Neurosteer
New York
About Neurosteer
Neurosteer® has developed a solution for the early detection and more effective treatment of a variety of neurological disorders. It consists of a medical-grade wearable device and cloud-based system that provides real-time monitoring and assessment of brain activity. The company’s current focus is on delivering objective biomarkers that identify the early onset of Parkinson’s, Alzheimer’s, dementia and epilepsy. Neurosteer uses an adhesive forehead strip connected to a pocket-sized device that wirelessly transmits sensor data to the cloud for proprietary signal processing. Advanced algorithms then decompose the single EEG channel into 100+ individual components for real-time analysis and display on a Web-based dashboard. The result is more affordable screening, continuous patient monitoring, and optimized neurostimulation and drug selection, leading to improved neurological treatment and outcome of clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $6.6M
- Funding stage: Seed
- Last round: Seed (Jun 2019)
- Website: neurosteer.com
- Phone: (401) 837-0351
Industries & Categories
Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/neurosteer-48491 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.